Oura has postponed its planned $2.2 billion Nasdaq IPO, leaving early investors and venture backers without an exit. The company had intended to sell 50 million shares at $40 to $44 per share, with 13.5 million being new stock and 36.5 million from existing holders. Forerunner Ventures planned to sell its entire 9.3% stake (~28.7 million shares), valued at roughly $1.2 billion at the $42 midpoint.

Lifeline Ventures was set to sell around 6.9 million shares. Cornerstone investors included Dragoneer Investment Group (up to $300 million) and Eli Lilly (up to $100 million). Oura expected net proceeds of about $532.6 million, primarily to cover tax withholding on employee RSUs.

The company reported 74% revenue growth to $1.21 billion for the nine months to June and $60.8 million in net income, stating it is profitable with 5.7 million paid members and expects 90% revenue growth in fiscal 2026. CEO Tom Hale said the company has “the luxury of choosing our moment”. The registration remains on file with the SEC, and Oura joins Holtec Nuclear, Amaero, and Bamboo Insurance in delaying or withdrawing IPOs amid market volatility.